Depyrogenated sterile empty vials market to hit $5.55 billion by 2030

The global market for depyrogenated sterile empty vials is projected to rise from $3.79 billion in 2025 to $4.09 billion in 2026, with North America holding the largest share last year. The report points to growing injectable drug production, biologics demand and tighter contamination controls as the main forces behind the expansion.

Why it matters: - Depyrogenated sterile empty vials are a core packaging component for injectable drugs, where contamination control is critical. - Rising use of biologics, vaccines and other injectables is pushing demand for sterile packaging across pharmaceutical supply chains. - The market’s growth matters for drug makers, contract manufacturers and packaging suppliers investing in aseptic fill-finish capacity.

What happened: - The Business Research Company released a market report on depyrogenated sterile empty vials on August 4, 2026. - The report values the market at $3.79 billion in 2025 and projects $4.09 billion in 2026. - The report forecasts the market will reach $5.55 billion by 2030. - North America held the largest share of the market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample and the full report are available here and here.

The details: - The market is growing at a 7.9% compound annual growth rate from 2025 to 2030. - Growth is being driven by higher injectable drug production, more sterile pharmaceutical manufacturing, stricter regulation around injectable safety and rising biologics and vaccine use. - Borosilicate glass packaging is a major product type supporting the market. - Depyrogenated sterile empty vials are borosilicate glass containers with butyl-rubber stoppers and aluminum seals. - Depyrogenation removes pyrogenic substances, including bacterial endotoxins, primarily through heat treatment. - The process is designed to meet safety standards for injectable drug storage and reduce contamination risk. - The vials are also used for collecting laboratory samples. - The report says biologics and biosimilars, aseptic fill-finish investment and contract manufacturing expansion will support future demand. - Other growth themes include contamination control, wider use of pre-sterilized packaging, regulatory compliance changes, high-purity injectable packaging, ready-to-fill vials and automated depyrogenation.

Between the lines: - The market is being pulled by both disease burden and manufacturing upgrades. - A February 2024 update from the UK Health Security Agency showed tuberculosis cases in England rose 10.7% in 2023 from 2022, from 4,380 to 4,850. - More infectious disease cases increase demand for injectable treatments that need sterile packaging. - North America’s lead reflects advanced pharmaceutical infrastructure, strict regulation and strong demand for injectables and vaccination programs. - Asia-Pacific and parts of Europe may grow faster as healthcare access and local pharmaceutical production expand.

What's next: - The report expects continued market momentum through 2030 as biologics and biosimilars gain share. - More investment in aseptic manufacturing and contract development and manufacturing services should support packaging demand. - The report’s 2026 edition adds TAM analysis, company scoring matrices, forecasting dashboards, hotspots infographics and updated trend analysis. - The Business Research Company lists Saumya Sahay as a contact for expert inquiries.